US EditionIlluccix Prostate Cancer PSMA-PET Imaging Agent Approved in Finland - PressReach
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Illuccix Prostate Cancer PSMA-PET Imaging Agent Approved in Finland - PressReach
MELBOURNE, Australia, April 30, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by Fimea[2] for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad …
Illuccix Prostate Cancer PSMA-PET Imaging Agent Approved in Finland
Illuccix Prostate Cancer PSMA-PET Imaging Agent Approved in Finland Melbourne (Australia) | 30 April 2025 Telix today announces that its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by Fimea[2] for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical lab…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
